ArticleFrontiers in endocrinology2025
A retrospective study: establishment and validation of the prediction model for the gonadotropin starting dose in IVF/ICSI-ET among normal ovarian response women.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to create and validate a clinical prediction model to determine the optimal gonadotropin (Gn) starting dose in controlled ovarian stimulation (COS) protocols for normal ovarian response (NOR) patients undergoing their first IVF/ICSI-ET cycle. Methods: A retrospective analysis was conducted based on the data of the first IVF/ICSI-ET cycles of 535 patients from the Reproductive Medicine Department of the Fourth Hospital of Hebei Medical University between January 2017 and June 2024. The patients were randomly divided into a training group (n=317) and a validation group (n=218) in a 6:4 ratio. Linear regression analysis was applied to screen out the potential factors influencing the Gn starting dose, and the statistically significant factors were selected to construct a nomogram for Gn dosage. We used an internal verification method to ensure the reliability of the nomogram. Results: The patient's age, body mass index (BMI), basal follicle-stimulating hormone (bFSH), antral follicle count (AFC), and anti-Müllerian hormone (AMH) were predictive indicators of the Gn starting dose for NOR patients undergoing IVF/ICSI-ET treatment ( Conclusion: Based on age, BMI, bFSH, AMH, and AFC, a clinician could determine the patient's appropriate Gn starting dose for NOR patients undergoing IVF/ICSI-ET.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.